AU1590201A - Compositions and methods for treating autoimmune diseases and transplant rejections - Google Patents

Compositions and methods for treating autoimmune diseases and transplant rejections

Info

Publication number
AU1590201A
AU1590201A AU15902/01A AU1590201A AU1590201A AU 1590201 A AU1590201 A AU 1590201A AU 15902/01 A AU15902/01 A AU 15902/01A AU 1590201 A AU1590201 A AU 1590201A AU 1590201 A AU1590201 A AU 1590201A
Authority
AU
Australia
Prior art keywords
compositions
methods
autoimmune diseases
treating autoimmune
transplant rejections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15902/01A
Inventor
Keting Chu
Changyu Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU1590201A publication Critical patent/AU1590201A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
AU15902/01A 1999-11-09 2000-11-08 Compositions and methods for treating autoimmune diseases and transplant rejections Abandoned AU1590201A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16450399P 1999-11-09 1999-11-09
US60164503 1999-11-09
PCT/US2000/030739 WO2001034649A2 (en) 1999-11-09 2000-11-08 Compositions and methods for treating autoimmune diseases and transplant rejections

Publications (1)

Publication Number Publication Date
AU1590201A true AU1590201A (en) 2001-06-06

Family

ID=22594784

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15902/01A Abandoned AU1590201A (en) 1999-11-09 2000-11-08 Compositions and methods for treating autoimmune diseases and transplant rejections

Country Status (2)

Country Link
AU (1) AU1590201A (en)
WO (1) WO2001034649A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP1294699B1 (en) 2000-05-12 2016-04-13 Genzyme Corporation Modulators of tnf- alpha signalling
EP1322383B9 (en) 2000-10-02 2006-09-06 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
EP1414483A1 (en) * 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
EP1562571B1 (en) * 2002-11-21 2011-08-17 Genzyme Corporation Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
WO2004047825A1 (en) 2002-11-21 2004-06-10 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CN1905897B (en) * 2003-11-04 2012-09-05 诺华疫苗和诊断公司 Antagonist anti-CD40 monoclonal antibodies and methods for their use
AU2006308606C1 (en) 2005-11-01 2013-07-25 Novartis Ag Uses of anti-CD40 antibodies
AR060487A1 (en) 2006-04-21 2008-06-18 Xoma Technology Ltd PHARMACEUTICAL COMPOSITIONS OF ANTI-BODY ANTAGONISTS ANTI-CD40
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
PE20180193A1 (en) 2015-05-29 2018-01-26 Abbvie Inc ANTI-CD40 ANTIBODIES AND THEIR USES
CN112409486B (en) * 2020-11-26 2022-05-20 杭州百凌生物科技有限公司 anti-CD 40 antibody and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
EP0945465B1 (en) * 1992-07-09 2006-09-13 Novartis Vaccines and Diagnostics, Inc. Antagonistic monoclonal antibodies to human CD40
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO2001024823A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis

Also Published As

Publication number Publication date
WO2001034649A3 (en) 2002-01-10
WO2001034649A2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
AU2327599A (en) Compositions and methods for treating autoimmune diseases
AU2002243231A1 (en) Method of treating autoimmune diseases
AU3387599A (en) Methods and compositions for tissue regeneration
AUPQ419099A0 (en) Novel compositions and methods
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU1590201A (en) Compositions and methods for treating autoimmune diseases and transplant rejections
AU7361900A (en) Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU2003297573A1 (en) Compositions and methods for treating transplants
AU6056500A (en) Process and composition for temporarily suppressing pain
AU2002235692A1 (en) Methods and compositions for preventing and treating neutrophil-mediated diseases
AU4033900A (en) Compositions and methods for treating cell proliferation disorders
AU4515001A (en) Compositions and methods for locally treating inflammatory diseases
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
EP1161575A4 (en) Nonsludging zinc phosphating composition and process
AU2055199A (en) Artificial fur and method for its manufacture
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU7686800A (en) Plant disease controlling compositions and plant disease controlling method
AU2003275433A1 (en) Compositions and methods for treating pain
AU2420101A (en) Method and composition for the treatment of pain
AU6234000A (en) Methods for treating autoimmune diseases
AU1477601A (en) Genetic compositions and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase